Don't worry, it will be approved for the latter soon enough, perhaps under a different brand. No way to put this genie back in the bottle, sorry.

Yes, this is what Novo Nordisk did with Victoza around 2014 with the release of Saxenda. And then again with Ozempic around 2021 with Wegovy. These weight loss versions exist. And there will be one likely this year based on tirzepatide from Lilly (I haven't looked up if they have a name for it yet).

The homepage is text and static images.. I doubt the issue is with them

I've recently been experimenting with a GLP-1 Agonist (Semaglutide) and it's had in incredible effect on my hunger levels and satiety. I find myself stopping in the middle of meals quite often and simply not enjoying the taste of what I'm eating as much. I wonder what the relationship between the dopaminergic effect of eating described in the article is with insulin secretion, blood sugar and GLP-1. I encourage anyone interested in this topic to look up GLP-1 Agonists very fascinating stuff.

If you're in the US, try a marketing pivot to minorities & the disadvantaged, then seek grants. Just a shot in the dark though.

Getting talent on the cheap

Cognitive overload.. Perhaps it'd be best to provide and example of a "verbose" variable name as compared to a "succinct"

Personally I'm thinking more along the lines of

Succinct ->KEY

Verbose -> MAIL_SERVICE_API_KEY

What's the cost?

Readability. In particular, an increase in the rate at which long, verbose names which are mostly the same are confused with one another.